Schisandrin B alleviates metabolic associated fatty liver disease by regulating the PPARγ signaling pathway and gut microbiota in mice
This study showed Sch B can improve HFD-induced MAFLD, and the mechanism may be through regulating the PPARγ, Plin2, PCk1, Acsl4 and Fads1 signaling pathway, restoring the diversity of gut microbiota, and improving the gut barrier to delay the progression of MAFLD.
Authors
- Jiayu Wan (ORCID: https://orcid.org/0000-0003-4603-3265)
- He Li (ORCID: https://orcid.org/0000-0002-8750-6404)
- Corinna N. Lang
- Meng Gao (ORCID: https://orcid.org/0000-0003-0706-2362)
- Chunmei Wang (ORCID: https://orcid.org/0000-0002-6358-511X)
- Xiaoqing Feng (ORCID: https://orcid.org/0000-0003-0971-8564)
- Jinghui Sun (ORCID: https://orcid.org/0000-0002-6417-0813)
- Feilong Liu (ORCID: https://orcid.org/0000-0002-6587-9752)
Institutions
- Beihua University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-07-25
- DOI
- https://doi.org/10.3389/fphar.2025.1583307
- Citations
- 3
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- National Natural Science Foundation of China
- People's Government of Jilin Province